StockData
Rhythm Pharmaceuticals, Inc. logo

Rhythm Pharmaceuticals, Inc. (RYTM) stock

RYTMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/30268% above fair value
$116.61+9.13 (+8.49%)

Close on Nov 17, 2026Market cap $8.03BP/E –Yield –

Rhythm Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Rhythm Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$200.63M. For fiscal 2025 it was -$192.02M. The highest annual figure on record is -$10.57M in fiscal 2015.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$192.02M–
FY2024Dec 31, 2024-$265.50M–
FY2023Dec 31, 2023-$184.36M–
FY2022Dec 31, 2022-$179.16M–
FY2021Dec 31, 2021-$170.06M–
FY2020Dec 31, 2020-$136.58M–
FY2019Dec 31, 2019-$146.00M–
FY2018Dec 31, 2018-$78.42M–
FY2017Dec 31, 2017-$32.41M–
FY2016Dec 31, 2016-$25.91M–
FY2015Dec 31, 2015-$10.57M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$48.55M–
Q1 FY2026Mar 31, 2026-$52.36M–
Q4 FY2025Dec 31, 2025-$47.06M–
Q3 FY2025Sep 30, 2025-$52.65M–
Q2 FY2025Jun 30, 2025-$45.30M–
Q1 FY2025Mar 31, 2025-$47.00M–
Q4 FY2024Dec 31, 2024-$41.26M–
Q3 FY2024Sep 30, 2024-$43.89M–
Q2 FY2024Jun 30, 2024-$40.48M–
Q1 FY2024Mar 31, 2024-$139.89M–
Q4 FY2023Dec 31, 2023-$41.27M–
Q3 FY2023Sep 30, 2023-$43.95M–
Q2 FY2023Jun 30, 2023-$46.60M–
Q1 FY2023Mar 31, 2023-$52.53M–
Q4 FY2022Dec 31, 2022-$42.10M–
Q3 FY2022Sep 30, 2022-$39.27M–
Q2 FY2022Jun 30, 2022-$45.10M–
Q1 FY2022Mar 31, 2022-$52.69M–
Q4 FY2021Dec 31, 2021-$50.99M–
Q3 FY2021Sep 30, 2021-$44.24M–
Q2 FY2021Jun 30, 2021-$40.43M–
Q1 FY2021Mar 31, 2021-$34.40M–
Q4 FY2020Dec 31, 2020-$35.07M–
Q3 FY2020Sep 30, 2020-$34.28M–
Q2 FY2020Jun 30, 2020-$31.92M–
Q1 FY2020Mar 31, 2020-$35.30M–
Q4 FY2019Dec 31, 2019-$34.22M–
Q3 FY2019Sep 30, 2019-$37.11M–
Q2 FY2019Jun 30, 2019-$44.15M–
Q1 FY2019Mar 31, 2019-$30.52M–
Q4 FY2018Dec 31, 2018-$27.15M–
Q3 FY2018Sep 30, 2018-$19.24M–
Q2 FY2018Jun 30, 2018-$15.02M–
Q1 FY2018Mar 31, 2018-$17.00M–
Q4 FY2017Dec 31, 2017-$10.98M–
Q3 FY2017Sep 30, 2017-$8.29M–
Q2 FY2017Jun 30, 2017-$6.75M–
Q1 FY2017Mar 31, 2017-$6.39M–
Q4 FY2016Dec 31, 2016-$8.38M–
Q3 FY2016Sep 30, 2016-$6.40M–

More Rhythm Pharmaceuticals figures

See a number that looks wrong?